CASCADIAN THERAPEUTICS, INC.
3101 Western Avenue, Suite 600
Seattle, Washington 98121
January 16, 2018
VIA EDGAR – Acceleration Request
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
| Attention: | Ruairi J. Regan |
| Re: | Cascadian Therapeutics, Inc. Registration Statement on FormS-3 (FileNo. 333-222362) filed December 29, 2017 |
Requested Date: January 18, 2018
Requested Time: 4:00 PM Eastern Time
Ladies and Gentlemen:
Cascadian Therapeutics, Inc. (the “Registrant”) hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to declare the above-captioned Registration Statement on Form S-3 effective at the “Requested Date” and “Requested Time” set forth above or as soon thereafter as practicable, or at such later time as the Registrant may orally request via telephone call to the staff of the Commission (the “Staff”).
The Registrant hereby authorizes Robert Freedman or Jane Jiang, both of whom are attorneys with the Registrant’s outside legal counsel, Fenwick & West LLP, to orally modify or withdraw this request for acceleration.
The Registrant requests that it be notified of such effectiveness by a telephone call to Ms. Jiang at(206) 389-4516 or, in her absence, to Mr. Freedman at(650) 335-7292.
[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]
Sincerely,
CASCADIAN THERAPEUTICS, INC. | ||
| By: | /s/ Julia M. Eastland | |
Julia M. Eastland Chief Financial Officer | ||
| cc: | Scott D. Myers, Chief Executive Officer |
Max Barker, Associate General Counsel
Cascadian Therapeutics, Inc.
Robert Freedman, Esq.
Jane Jiang, Esq.
Fenwick & West LLP
